Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EVONIK INDUSTRIES AG

(EVK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evonik Industries : boosts its system solutions portfolio with the acquisition of the cosmetic delivery company Infinitec Activos

06/15/2021 | 04:06am EDT
  • Strong technological and strategic fit supports the portfolio shift of Evonik's life science division Nutrition & Care towards system solutions
  • Evonik enhances its capabilities to generate new concepts for scientifically substantiated consumer claims
  • Evonik strengthens its existing active delivery business with seven additional proprietary delivery systems and enlarges its bio actives portfolio with several new natural-based active ingredients

Essen, Germany. Evonik has signed a purchase agreement to acquire the privately owned technology-driven company Infinitec Activos, with closing expected by July. The Spanish company focuses on the development and production of novel active delivery systems for cosmetic active ingredient applications. Infinitec Activos will be integrated into the Care Solutions business line of Evonik's Nutrition & Care division complementing the active delivery systems acquired in 2017.

This latest acquisition continues the portfolio shift of Evonik's life science division Nutrition & Care towards system solutions, which are characterized by high growth prospects and above average margin potential. Nutrition & Care aims to increase the share of system solutions it offers from 20 percent today, to more than 50 percent by 2030.

'Proven active delivery systems offer great opportunities to innovate new cosmetic ingredients with scientifically proven claims. This allows our personal care customers to differentiate,' said Yann d'Hervé, head of Evonik's Care Solutions business line.

With its portfolio of natural-based active ingredients and seven delivery systems, the integration of Infinitec Activos into the Care Solutions business line reinforces Evonik's position as a sustainable specialties partner, while also further strengthening Nutrition & Care's wide technology platform. By combining its existing actives portfolio with the new delivery systems, Care Solutions' capabilities to generate new concepts for scientifically substantiated consumer cosmetic claims are significantly enhanced. The integration and roll-out across the existing platform of cosmetic solutions offers strong synergy potential.

'We are convinced that the synergies created will not only bring benefits to our customers and both companies, but also create new opportunities across the entire personal care and beauty market value chain,' said Alfonso Hidalgo, Partner of Infinitec Activos S.L.

Infinitec Activos continues the strong acquisition track record of Nutrition & Care. Since 2016, the division has acquired ten companies with strong and complementary technology positions enhancing the entire product portfolio. Their successful integration has opened new markets, accelerated growth and created significant value.

The acquisition comprises 47 employees working at the company's Barcelona Science Park head office, its manufacturing facility in Montornés del Vallès (Spain) and at its natural-based raw material producer, Naturethic. Founded in 2004, Infinitec Activos' research and innovation focusses on building the next generation of cosmetic delivery systems with a highly qualified, science- and marketing-driven team. Customers include both small independent brands as well as global key accounts..

Infinitec Activos provides customers with individualised products. One example is its renowned, actively targeted, Cosmetic Drone proprietary technology, as well as its next-generation of PLGA (poly(lactic-co-glycolic acid))-based delivery system. The Company's new generation of actively targeted delivery system decorates surface particles with two peptides for dual-mode cellular targeting, while its core has been loaded with the desired active ingredient. Evonik expects to leverage the intellectual property in adjacent markets such as Health Care where it has already deployed its liposomal delivery technology.

Disclaimer

Evonik Industries AG published this content on 15 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2021 08:05:03 UTC.


ę Publicnow 2021
All news about EVONIK INDUSTRIES AG
08/02EVONIK INDUSTRIES : acquires German biotech company JeNaCell to expand biomateri..
PU
07/26EVONIK INDUSTRIES AG : Preliminary announcement of the publication of financial ..
EQ
07/26DGAP-AFR : Evonik Industries AG: Preliminary announcement of the publication of ..
DJ
07/23EVONIK INDUSTRIES : presents its latest 'Living polyurethanes' solutions for imp..
AQ
07/22EVONIK INDUSTRIES : presents its latest “Living polyurethanes” solut..
PU
07/15EVONIK : Sell rating from Baader Bank
MD
07/14EVONIK INDUSTRIES : new emissions testing facility enables more sustainable poly..
PU
07/13EVONIK : Warburg Research reaffirms its Neutral rating
MD
07/12THE ROAD TO GREATER ENERGY EFFICIENC : MACBETH project reaches important milesto..
PU
07/09EVONIK - MILESTONE IN MARL : Minister President Armin Laschet inaugurates world'..
AQ
More news
Financials
Sales 2021 13 366 M 15 868 M 15 868 M
Net income 2021 761 M 904 M 904 M
Net Debt 2021 2 621 M 3 112 M 3 112 M
P/E ratio 2021 18,2x
Yield 2021 3,93%
Capitalization 13 775 M 16 371 M 16 353 M
EV / Sales 2021 1,23x
EV / Sales 2022 1,17x
Nbr of Employees 32 745
Free-Float 41,1%
Chart EVONIK INDUSTRIES AG
Duration : Period :
Evonik Industries AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVONIK INDUSTRIES AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 29,56 €
Average target price 31,35 €
Spread / Average Target 6,05%
EPS Revisions
Managers and Directors
Christian Kullmann Chairman-Executive Board
Ute Wolf Chief Financial Officer
Bernd T÷njes Chairman-Supervisory Board
Andreas Fischer Chief Innovation Officer
Siegfried Luther Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
EVONIK INDUSTRIES AG10.79%16 371
BASF SE2.10%72 149
SHIN-ETSU CHEMICAL CO., LTD.1.47%67 205
DUPONT DE NEMOURS, INC.4.98%39 937
ROYAL DSM N.V.21.13%34 430
PIDILITE INDUSTRIES LIMITED28.17%15 569